Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | ESRRG | P62508 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6445761 | 0.89 | ESRRG (0.55) | GAACA12CA1CA7CA14 | |
| SCHEMBL9971059 | 0.87 | GAA (0.51) | GAACA12CA1CA7CA14 | |
| SCHEMBL4025879 | 0.86 | GAA (0.68) | GAACA12CA1CA7CA14 | |
| SCHEMBL1668799 | 0.86 | GAA (0.50) | GAACA12CA1CA7CA14 | |
| SCHEMBL13903558 | 0.86 | ESRRG (0.60) | GAACA1ESRRGMEN1KMT2A | |
| SCHEMBL4632779 | 0.85 | CA12 (0.60) | GAACA12CA1CA7CA14 | |
| SCHEMBL2493016 | 0.84 | NPC1 (0.49) | GAAPPARGPPARAMEN1KMT2A | |
| SCHEMBL5796279 | 0.83 | L3MBTL1 (0.56) | GAACA1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12643777 | 0.83 | GAA (0.58) | GAAMEN1KMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL8203874 | 0.83 | RAB9A (0.56) | GAACA12CA1CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062358-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | CANO IVAN COLLADO | 2009-03-05 | — | — | US | disclosed |
| US-20090062358-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | CANO IVAN COLLADO | 2009-03-05 | — | — | US | disclosed |
| EP-1335908-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | LILLY CO ELI (US) | 2008-02-13 | — | — | EP | disclosed |
| US-7304062-B2 | Peroxisome proliferator activated receptor alpha agonists | ELI LILLY AND COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304062-B2 | Peroxisome proliferator activated receptor alpha agonists | ELI LILLY AND COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1004582-B1 | Pyridazino quinoline compounds | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | EP | disclosed |
| EP-0790996-B1 | PYRIDAZINOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-03-27 | — | — | EP | disclosed |
| US-6232313-B1 | TREATING STROKE OR EPILEPTIC CONVULSIONS ASSOCIATED WITH EXCESSIVE CALCIUM INFLUX IN THE BRAIN CAUSED BY EXCITATORY AMINO ACIDS | ZENECA LIMITED (GB) | 2001-05-15 | — | — | US | disclosed |
| US-6214826-B1 | NERVOUS SYSTEM DISORDERS | ZENECA LIMITED (GB) | 2001-04-10 | — | — | US | disclosed |
| EP-0724583-B1 | PYRIDAZINO QUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-12-13 | — | — | EP | disclosed |
| US-5744471-A | NERVOUS SYSTEM DISORDERS | ZENECA LIMITED (GB) | 1998-04-28 | — | — | US | disclosed |
| EP-0790996-A1 | PYRIDAZINOQUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| US-5631376-A | PEPTIDE DERIVATIVES FOR TREATMENT OF AIDS | ABBOTT LABORATORIES (US) | 1997-05-20 | — | — | US | disclosed |
| US-5621109-A | OXAZOLE/THIAZOLE DERIVATIVES OF HYDROXYMETHYL HYDRAZONES; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0724583-A1 | PYRIDAZINO QUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1996-08-07 | — | — | EP | disclosed |
| WO-1996015127-A1 | PYRIDAZINOQUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
| US-5461067-A | For HIV infections | ABBOTT LABORATORIES (US) | 1995-10-24 | — | — | US | disclosed |
| EP-0672678-A1 | Azapeptide derivative | FUJIREBIO Inc. (JP) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995011244-A1 | PYRIDAZINO QUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1995-04-27 | — | — | WO | disclosed |
| WO-1994019332-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062358-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | PPARG, PPARA, PPARD | GAA 3979/4885CA12 3953/4885CA1 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.